October is Breast Cancer Awareness Month and there tends to be some misinformation that floats around regarding what does or doesn't contribute to the disease.
"We look at awareness not just as wearing pink or buying something to support research, but as essential healthcare, and so we need to make sure that all women understand what to look for, what to feel for and to be able to come back to us if there's anything of concern to them", Lytle-Barnaby says. According to Cancer Research UK, breast cancer survival rates are improving and have doubled in the last 40 years in the UK, although they continue to lag behind those in other European countries.
Medical professionals at Breast Cancer Now, have predicted that millennials may have more to worry about when it comes to breast cancer compared to other generations.
The Health Promotion Administration (HPA) yesterday said mammography is the most effective method to screen for breast cancer and getting regular exams reduces the risk of death.
"It's just something we'll be doing year after year after year", Hoskins said. There is slightly more radiation involved with a 3D mammogram, but fewer women have to return for a second mammogram because of the new technology.
"That means", Couch says, "doctors should consider that women who have any of these mutations will have an increased risk for triple negative breast cancer".
TNBC tends to be more aggressive than other common types of breast cancer. If you or someone you know are now going through this, you are not alone. "Since radionuclides are used in imaging and locating tumors, we can now simultaneously image and treat breast cancer metastasis using the same radionuclide", says the researcher. They'll pay for an ultrasound of your ovaries. Fibrous connective tissues also get affected or the fatty tissues of the breasts can also develop cancer.
"It's important to note that most lumps are not cancerous, but women should have them checked by a health care provider", she said. "There are more survivors than ever before", Roberts said.
Authors concluded in their study, "Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant".
The charity helps towards funding cutting-edge research across the United Kingdom and Ireland to help find a cure for breast cancer at all stages. We have better treatments. "So, we're finding it earlier, we're treating it better, and people are surviving longer".